title: Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used.
abstract: Patients undergoing autologous hematopoietic stem cell transplantation (auto-HSCT) for autoimmune disease may have an added propensity to develop a second autoimmune disorder, given the genetic predisposition to autoimmunity. Therefore, we undertook a retrospective analysis of all patients who have undergone auto-HSCT for an autoimmune disease in our institution to determine the occurrence of a second autoimmune disorder and possible risk factors. In all, 155 patients underwent auto-HSCT for various autoimmune diseases; of those patients, 6 manifested a distinct secondary autoimmune disease at a median of 8.5 months (range, 2-30 months) after auto-HSCT. There were 2 patients with systemic lupus erythematosus, conditioned with a regimen containing antithymocyte globulin (ATG), who developed factor VIII inhibitors with severe bleeding. There were 4 patients (2 with multiple sclerosis, one each with lupus and systemic sclerosis) who received an alemtuzumab-containing conditioning regimen who developed autoimmune cytopenias. Among the 155 patients, the frequency of secondary autoimmune complications was 16.0% with alemtuzumab (4/25), 1.9% for ATG (2/102), and 0% for conditioning regimens without lympho-depleting antibodies (0/28)-a difference that was found to be significantly higher with alemtuzumab exposure (P = .011). In contrast, sex, type of ATG used, and CD34-selection of peripheral blood stem cells were not found to be significantly associated with development of a secondary autoimmune disorder.
authors.affiliation: Division of Immunotherapy, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Loh
authors.forename: Yu
authors.initials: Y
authors.lastname: Oyama
authors.forename: Laisvyde
authors.initials: L
authors.lastname: Statkute
authors.forename: Kathleen
authors.initials: K
authors.lastname: Quigley
authors.forename: Kimberly
authors.initials: K
authors.lastname: Yaung
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Gonda
authors.forename: Walter
authors.initials: W
authors.lastname: Barr
authors.forename: Borko
authors.initials: B
authors.lastname: Jovanovic
authors.forename: Robert
authors.initials: R
authors.lastname: Craig
authors.forename: Dusan
authors.initials: D
authors.lastname: Stefoski
authors.forename: Bruce
authors.initials: B
authors.lastname: Cohen
authors.forename: Richard K
authors.initials: RK
authors.lastname: Burt
mesh_terms: D000328:Adult; D001327:Autoimmune Diseases / Q000276:immunology* / Q000378:metabolism / Q000473:pathology*; D005169:Factor VIII / Q000037:antagonists & inhibitors / Q000378:metabolism; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D019172:Transplantation Conditioning / Q000379:methods*
chemical_list: D005169:Factor VIII